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ABSTRACT
Purpose: BRCA1/2 mutations are associated with risks of breast and ovarian cancer. In Korea, 
incidences of BRCA1/2 genetic testing and risk-reducing surgery (RRS) have increased with 
insurance coverage and the Angelina Jolie effect. The aim of this study was to identify trends 
in RRS performed in Korean women with the BRCA1/2 mutation.
Methods: We retrospectively reviewed the medical records of BRCA1/2 mutation carriers with 
(affected carriers) and without (unaffected carriers) breast cancer until August 2018 from 25 
Korean Hereditary Breast Cancer (KOHBRA)-affiliated hospitals.
Results: The numbers of contralateral risk-reducing mastectomy (RRM) and risk-reducing 
bilateral salpingo-oophorectomy (RRBSO) in affected carriers have increased 5.8- and 3.6-
fold, respectively, since 2013. The numbers of RRBSO in unaffected carriers has increased 
8-fold since 2013. The number of institutions that perform RRS has increased gradually. The 
number of hospitals that perform contralateral RRM on affected carriers increased from 3 in 
2012 to 11 in 2018, and that of those that perform RRBSO increased from 7 to 17. The number 
of hospitals that perform bilateral RRM on unaffected carriers increased from 1 in 2012 to 2 
in 2018, and that of those that perform RRBSO increased from 1 to 8. However, the hospitals 
showed differences in the rates of RRM or RRBSO performed.
Conclusion: The incidence of RRS increased each year throughout the study period. However, 
in Korea, the rate of RRS procedures depended on the hospital.
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INTRODUCTION
The most common causative gene of hereditary breast cancer is BRCA1/2, with mutations in 
these genes accounting for almost 25% of families with a strong history of breast cancer [1]. 
The estimated lifetime risks are 56%–80% for breast cancer and 27%–45% for ovarian cancer 
in carriers of the BRCA1 mutation, and 45%–84% for breast cancer and 10%–20% for ovarian 
cancer in carriers of the BRCA2 mutation [2-4]. Results from the Korean Hereditary Breast 
Cancer (KOHBRA) study have helped improve clinicians' recognition of hereditary breast 
cancer, especially in Korea [5-7].
Carriers of the BRCA1/2 mutation are recommended to undergo annual breast magnetic 
resonance imaging for screening or receive risk-reducing management procedures such 
as chemoprevention or risk-reducing surgery (RRS). In Korea, RRS for breast and ovarian 
cancer prevention was not widely performed before 2012. However, the National Health 
Insurance initiated insurance coverage of BRCA1/2 genetic testing in May 2012. In addition, 
the actress Angelina Jolie—a carrier of the BRCA1 mutation—announced her decision to 
undergo a bilateral risk-reducing mastectomy (RRM) in May 2013. Following these events, 
more women took interest in BRCA1/2 mutations, and the frequency of RRS has increased 
over the past decade [8].
In a previous study, we reported the trends in RRS and BRCA1/2 genetic testing from 2010 to 
2015 [9]. Insurance for risk-reducing bilateral salpingo-oophorectomy (RRBSO) has been 
available since December 2012. Subsequently, insurance coverage of RRM with or without 
breast reconstruction was initiated in October 2017. The aim of this study was to investigate 
trends in RRS for the prevention of breast and ovarian cancer in Korean carriers of the 
BRCA1/2 mutation until August 2018.
METHODS
Affected carriers were defined by BRCA1/2 mutation with breast cancer, and unaffected 
carriers were defined by BRCA1/2 mutation without breast cancer. Overall, 25 KOHBRA-
affiliated hospitals agreed to participate in this study, with 18 hospitals subsequently 
providing data. The data were retrospectively collected from patients' medical records. In 
addition, the number of BRCA1/2 genetic tests performed by the Health Insurance Review and 
Assessment Service was investigated. The numbers of genetic testing for BRCA1/2 mutations 
and RRS were collected from January 2010 to August 2018.
The 25 KOHBRA-affiliated hospitals were Bunhongbit Hospital, Chonbuk National University 
Hospital, Daegu Catholic University Medical Center, Daejeon St. Mary's Hospita, Daerim 
Saint Mary's Hospital, Dankook University Hospital, Dongguk University Ilsan Hospital, 
Gangnam Severance Hospital, Gangwon National University Hospital, Inje University Ilsan 
Paik Hospital, Korea Cancer Center Hospital, Korea University Anam Hospital, Kwangju 
christian hospital, Kyunghee University Medical Center, Kyungpook National University 
Hospital, National Cancer Center, Samsung Medical Center, Seoul Asan Hospital, Seoul 
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National University Bundang Hospital, Seoul National University Hospital, Seoul St. Mary's 
Hospital, Severance Hospital, Soonchunhyang University Bucheon Hospital, Soonchunhyang 
University Cheonan Hospital, and Ulsan University Hospital.
Statistical analyses were performed using SPSS Statistics version 25 (IBM Corp., Armonk, 
USA). The χ2 test and Fisher's exact test were conducted to compare categorical variables 
between the 2 groups. The categorical variables are reported here as number (percentage). 
The Wilcoxon signed rank test was used to analyze the difference in numbers of RRS 
performed among BRCA1/2 mutation carriers before and after Angelina Jolie's announcement. 
Statistical significance was defined as p < 0.05 in all tests.
This study followed the principles outlined in the Declaration of Helsinki and was approved 
by the Institutional Review Board of Samsung Medical Center (IRB file No. 2020-03-021-001). 
The need for informed consent was waived because of the low risk posed by this investigation.
RESULTS
In Korea, BRCA1/2 genetic testing has rapidly increased 10-fold from 578 cases in 2010 to 
5,880 cases in 2017 (Figure 1). Of 19,033 patients who underwent BRCA1/2 genetic testing, 
1,752 (9.2%) carriers of the BRCA1/2 mutation were divided into two groups: 1238 affected 
carriers and 514 unaffected carriers (Table 1).
The numbers of RRM and RRBSO performed increased moderately during the period 
investigated. Among 1,238 affected carriers, contralateral RRM was performed in 122 (9.9%) 
patients, and RRBSO in 428 (34.6%) patients until August 2018. Among 514 unaffected 
649https://ejbc.kr https://doi.org/10.4048/jbc.2020.23.e61


































Figure 1. Annual trends in BRCA1/2 genetic testing in South Korea.
Table 1. Number of RRS in BRCA1/2 mutation carrier until August 2018
Variables BRCA1/2 mutation carrier with 
breast cancer
BRCA1/2 mutation carrier without 
breast cancer
No. of BRCA1/2 mutation carrier 1,238 514
RRM 122 (9.9%) 6 (1.2%)
RRBSO 428 (34.6%) 61 (11.9%)
RRS = risk-reducing surgery; RRM = risk-reducing mastectomy; RRBSO = risk-reducing bilateral salpingo-
oophorectomy.
carriers, bilateral RRM and RRBSO were performed in 6 (1.2%) and 61 (11.9%) patients, 
respectively, until August 2018 (Table 1). Contralateral RRM among affected carriers 
increased approximately 5.8-fold, from 5 cases in 2013 to 29 cases in 2017. RRBSO among 
affected carriers also increased approximately 3.6-fold, from 22 cases in 2013 to 79 cases 
in 2017. Among unaffected carriers, bilateral RRM increased by 1 case in 2017, and RRBSO 
increased 8-fold from 2 cases in 2013 to 16 cases in 2017 (Figure 2). There were significant 
differences in the rate of contralateral RRM in affected carriers and RRBSO in BRCA1/2 
mutation carriers before and after Angelina Jolie's announcement (p < 0.05); however, there 
was no difference in the rate of bilateral RRM in unaffected carriers (Table 2).
The number of institutions that performed RRS increased gradually. The number of 
institutions performing contralateral RRM in affected carriers increased from 3 in 2012 to 11 
in 2018, and that of those performing RRBSO increased from 7 to 17 in the same time frame. 
The number of institutions that performed bilateral RRM in unaffected carriers increased 
from 1 in 2012 to 2 in 2018, and that of those performing RRBSO increased from 1 in 2012 to 
8 in 2018.
Hospitals in Korea showed differences in the rates of RRM and RRBSO. Among affected 
carriers treated at different hospitals, the highest and lowest rates of contralateral RRM were 
44.4% and 2.9%, respectively, while those of RRBSO were 100% and 12.7%, respectively 
(Figures 3 and 4). Among unaffected carriers, the highest and lowest rates of RRS were 11.1% 
and 7.4% for bilateral RRM, and 80% and 2.0% for RRBSO, respectively (Figures 5 and 6). 
However, there was no significant difference in the rate of RRM or RRBSO by level of care. Of 
the 18 hospitals that provided data, 4 hospitals were secondary and 14 were tertiary. Among 
affected carriers treated at secondary and tertiary hospitals, the rates of contralateral RRM 
were 11.8% and 9.8%, and the rates of RRBSO were 23.5% and 34.9%, respectively. Among 
unaffected carriers treated at secondary and tertiary hospitals, the rates of bilateral RRM were 
0.0% and 1.2%, and the rates of RRBSO were 3.4% and 12.4%, respectively (Tables 3 and 4).
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Figure 2. Annual trends for risk-reducing surgery in (A) affected carriers and (B) unaffected carriers.
Table 2. The Angelina Jolie effect on trends for RRS in BRCA1/2 mutation carriers
Variables Before 2012 After 2013 p-value
Contralateral RRM affected carrier 11 (9.0%) 111 (91.0%) 0.003
Bilateral RRM unaffected carrier 3 (50.0%) 3 (50.0%) 1.000
RRBSO affected carrier 43 (10.0%) 385 (90.0%) <0.001
RRBSO unaffected carrier 4 (6.6%) 57 (93.4%) 0.007
RRS = risk-reducing surgery; RRM = risk-reducing mastectomy; RRBSO = risk-reducing bilateral salpingo-
oophorectomy.
DISCUSSION
This study was conducted by collecting and analyzing data from multiple centers affiliated 
with the KOHBRA study that was conducted until May 2013. We retrospectively reviewed 
annual trends in BRCA1/2 genetic testing and RRS in KOHBRA-affiliated hospitals until August 
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Figure 5. Rate of bilateral risk-reducing mastectomy in unaffected carriers by institution.
2018. Our study showed that while the rates of BRCA1/2 genetic testing and RRS have increased 
rapidly, there are differences in the number of RRS performed among hospitals in Korea.
The prevalence of BRCA1/2 genetic testing and RRS have continued to increase because of the 
global rise in numbers of laboratories offering genetic testing, expanding insurance coverage, 
celebrity endorsement, and evidence for the clinical benefits of known mutational status [3,9]. 
In Korea, the KOHBRA study (2007–2013) established a large cohort of BRCA1/2 mutation 
carriers among Korean breast cancer patients [7], and has improved clinician awareness of 
the BRCA 1/2 mutation. In addition, insurance reimbursement for hereditary breast cancer 
has been enacted in Korea over the past 10 years. Korea is the only Asian country that offers 
national insurance to patients with breast cancer for BRCA1/2 genetic testing.
Moreover, the disclosure of Angelina Jolie's medical history was followed by increasing 
BRCA1/2 genetic testing and RRS in Korea. Jolie underwent RRM in May 2013 and RRBSO in 
March 2015, and these announcements helped create global awareness about BRCA1/2 genetic 
testing and RRS. We found that RRBSO in BRCA1/2 mutation carriers increased significantly 
after Jolie's announcement. Contralateral RRM in affected carriers also increased 
significantly; however, there was no significant difference in bilateral RRM in unaffected 
carriers. Many studies have reported the international trends in BRCA1/2 genetic testing and 
RRM after Jolie's announcement. For instance, Desai and Jena [10] found that the rate of 
RRM remained unchanged after news coverage about Jolie's diagnosis, although BRCA1/2 
genetic testing increased significantly. However, several other studies showed an increase 
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Figure 6. Rate of risk-reducing bilateral salpingo-oophorectomy in unaffected carriers by institution.
Table 3. Rate of RRS in affected carriers by level of care until August 2018
Variables Secondary Tertiary p-value
No. of BRCA1/2 mutation carrier 34 1,204
Contralateral RRM 4 (11.8%) 118 (9.8%) 0.768
RRBSO 8 (23.5%) 420 (34.9%) 0.170
RRS = risk-reducing surgery; RRM = risk-reducing mastectomy; RRBSO = risk-reducing bilateral salpingo-
oophorectomy.
Table 4. Rate of RRS in unaffected carriers by level of care until August 2018
Variables Secondary Tertiary p-value
No. of BRCA1/2 mutation carrier 29 485
Bilateral RRM 0 (0.0%) 6 (1.2%) 1.000
RRBSO 1 (3.4%) 60 (12.4%) 0.234
RRS = risk-reducing surgery; RRM = risk-reducing mastectomy; RRBSO = risk-reducing bilateral salpingo-
oophorectomy.
in bilateral RRM in an international database of BRCA1/2 mutation carriers who had recently 
undergone genetic testing [3,11]. The uptake of RRM by unaffected carriers varied greatly 
among countries [3,12]. Metcalfe et al. [3] reported an increase in RRM in 10 countries, 
with the highest uptake of bilateral RRM being in the United States (49.9%) and the lowest 
in Poland (4.5%). In Korea, the uptake of RRM was 1.2% in unaffected carriers and 9.9% in 
affected carriers until August 2018. By August 2018, BRCA1/2 mutation carriers were more 
likely to choose RRM than they had been in the preceding decade. The impact of insurance 
coverage and Angelina Jolie's news resulted in changes in thinking about RRS in Korea.
The increase in numbers of clinicians and hospitals that perform RRS has also affected its 
uptake, although there are differences in rates of RRS among hospitals in Korea. The lack of 
significant differences in rates of RRS between secondary and tertiary hospitals may be due 
to RRS being actively recommended in only a few hospitals, regardless their level of care. The 
difference in rates among hospitals may be attributed to differences in the clinician's choices, 
time for genetic testing results, genetic counseling, or multidisciplinary teams between 
hospitals. It will be necessary to improve the medical environment and clinicians' awareness, 
so that more clinicians and hospitals may consider the result of BRCA1/2 genetic testing more 
carefully, which may further affect decision-making for RRS.
Risk-reducing management of BRCA1/2 mutation carriers has occurred worldwide [13,14]. In 
carriers of the BRCA1/2 mutation, RRM lowers the risk of breast cancer by approximately 90% 
[15,16]. RRBSO is associated with a 70% reduction in the risk of ovarian cancer in unaffected 
carriers and an 85% reduction in affected carriers [17]. RRBSO also lowers the risk of breast 
cancer by 37% in BRCA1 mutation carriers and by 64% in BRCA2 mutation carriers [17]. The 
current National Comprehensive Cancer Network guidelines recommend RRBSO for BRCA1 
mutation carriers who are aged between 35 and 40 years and have completed childbearing 
[18]. Since the onset of ovarian cancer occurs an average of 8–10 years later in BRCA2 mutation 
carriers than in those with the BRCA1 mutation, RRBSO is recommended until the age of 
40–45 years in the former [18]. In unaffected carriers, survival benefits are apparent for 
RRBSO, but not for RRM. However, Heemskerk-Gerritsen et al. [19] reported that RRM is 
associated with lower mortality than surveillance for carriers of the BRCA1 mutation [20,21]. 
Metcalfe et al. [22] showed that mortality risk was lower in patients with BRCA1/2 mutation who 
were treated for stage I or II breast cancer with bilateral mastectomy that those treated with 
unilateral mastectomy. Although RRS is recommended for carriers of the BRCA1/2 mutation, 
the procedure has adverse psychosocial and sexual effects because it removes normal breasts or 
ovaries. Moreover, sensory changes and skin necrosis may be caused by RRM, and RRBSO may 
have adverse effects on lipid profiles and may increase the risk of cardiovascular disease and 
osteoporosis. Because of the benefits and harms of RRS, clinicians should play a major role in 
the decision-making process of RRM or RRBSO for carriers of the BRCA1/2 mutation [13,23,24].
The results of BRCA1/2 genetic testing before surgery may help affected carriers decide 
whether to undergo contralateral RRM. Traditional Sanger sequencing analysis for BRCA1/2 
mutation has a high cost and long turnaround time (TAT) due to the large size of the genes 
[25]. Next‐generation sequencing (NGS) allows simultaneous sequencing of multiple cancer 
susceptibility genes, and may be less expensive. NGS can also have a shorter TAT and higher 
accuracy than conventional methods [25,26], which can allow clinicians and patients to make 
decisions about RRS. In Korea, insurance coverage of NGS for BRCA1/2 genetic testing started 
in September 2017, and both BRCA1/2 genetic testing and RRS are likely to gradually increase 
in frequency. Further research is needed on this trend in Korea.
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This study demonstrated an increasing incidence of BRCA1/2 genetic testing and RRS in 
consecutive years. However, differences in RRS rates depend on the hospital in Korea. 
We need to provide enough information for patients to understand the results of genetic 
counseling so that they can make the optimal choice of treatment.
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